Navigation Links
Emisphere to Host Business Strategy Conference Call on February 7
Date:1/31/2008

- CEO Michael V. Novinski to Discuss Plans for Company in 2008 and Beyond -

CEDAR KNOLLS, N.J., Jan. 31 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), announced today that it will host a teleconference on Thursday, February 7, at 10:00 AM EST. President and Chief Executive Officer Michael V. Novinski will discuss the company's emerging business strategy. Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its eligen(R) technology.

A live Webcast of the conference call can be accessed through the company's web site at http://www.emisphere.com. The live conference call dial-in number is: 1-888-264-8952 (U.S. and Canada) or 1-913-312-0654 (International). In addition, an archive of the Webcast can be accessed through the same link; an audio replay of the call will be available following the conference call by calling 1-888-203-1112 (U.S. and Canada) or 1-719-457-0820 (International). The conference replay PIN is 871428. A slide deck will be available on the Emisphere web site at the time of the call.

"Emisphere's investor base is a valued resource," said Michael V. Novinski, President and Chief Executive Officer of Emisphere Technologies, Inc. "Our teleconference will provide investors with a better understanding of where we are taking the company and what opportunities lie ahead."

About Emisphere Technologies, Inc.

Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules using its eligen(R) technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The eligen(R) technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The Web site is http://www.emisphere.com.

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, or Emisphere's ability to fund such efforts with or without partners. Emisphere undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 000-17758) filed on March 6, 2007, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, filed on May 7, 2007 (file no. 000-17758) and for the quarter ended June 30, 2007, filed on August 7, 2007 (file No. 000-17758).


'/>"/>
SOURCE Emisphere Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Emisphere Technologies, Inc. Moves Into New Corporate Headquarters
2. Emisphere Technologies, Inc. Appoints Gary Riley as Vice President Nonclinical Development & Applied Biology
3. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
4. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
5. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. Medefield Announces New Appointments to North American Business Unit
8. Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress
9. Clinimetrics Celebrates 20th Anniversary in Contract Research Business
10. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
11. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 29, 2016 , ... Amendia, Inc., a leading designer, developer, ... the completion of a significant transaction and partnership that positions Amendia for accelerated ... Kohlberg & Company, L.L.C. (“Kohlberg”), a leading private equity firm specializing in ...
(Date:4/29/2016)... ... ... Implant Systems announced today that the two-level components for the Revolution™ Spinal System were ... components expand the capabilities of the system and allow Revolution™ to be utilized for ... company has seen significant sales growth in 1Q 2016, and the system is currently ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... and ongoing support for Connecticut's innovative, growing companies, today announced the launch of ... and financial technology (fintech) companies. , “VentureClash looks to attract the ...
(Date:4/27/2016)... ... April 27, 2016 , ... Cambridge Semantics, the ... technology, today announced that it has been named to The Silicon Review’s “20 Fastest ... and other markets, Cambridge Semantics serves the needs of end users facing some of ...
Breaking Biology Technology:
(Date:3/3/2016)... , March 3, 2016  FlexTech, a SEMI ... categories of Innovation, Research & Development, Leadership in Education, ... This is the 9 th year of the ... of companies and individuals from past years . ... on a pre-described set of criteria, by a panel ...
(Date:3/2/2016)... March 2, 2016 ... addition of the  "Global Biometrics Market in ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , Global biometrics ... at a CAGR of around 27%   ... has announced the addition of the  "Global ...
(Date:3/1/2016)... SAN FRANCISCO , March 1, 2016  (RSAC ... every year, but a whopping $118 billion is lost ... due to overzealous and inaccurate fraud detection. At the ... shift in the way companies handle authentication by devaluing ... biometric and behavioral analytics. --> ...
Breaking Biology News(10 mins):